Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.50 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | PFKFB2 | O60825 | 1/20 | 0.38 |
| ▸ | PFKFB1 | P16118 | 1/20 | 0.38 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186728 | 0.86 | CSNK2A1 (0.58) | IMPDH2IMPDH1CCNT1CDK9HASPIN | |
| SCHEMBL188007 | 0.85 | IMPDH2 (0.61) | IMPDH2IMPDH1CCNT1CDK9HASPIN | |
| SCHEMBL29388515 | 0.78 | IMPDH2 (0.47) | IMPDH2IMPDH1CCNT1CDK9HASPIN | |
| SCHEMBL12680482 | 0.78 | IMPDH2 (0.47) | IMPDH2IMPDH1CCNT1CDK9HASPIN | |
| SCHEMBL12680441 | 0.77 | ESR2 (0.44) | IMPDH2IMPDH1CCNT1CDK9HASPIN | |
| SCHEMBL12680430 | 0.77 | IMPDH2 (0.50) | IMPDH2IMPDH1CCNT1CDK9HASPIN | |
| SCHEMBL578797 | 0.76 | IMPDH2 (0.56) | IMPDH2IMPDH1CCNT1CDK9HASPIN | |
| SCHEMBL30665808 | 0.76 | IMPDH2 (0.56) | IMPDH2IMPDH1CCNT1CDK9HASPIN | |
| SCHEMBL22221034 | 0.75 | LMNA (0.43) | IMPDH2IMPDH1SLC6A4SLC6A2PFKFB2 | |
| SCHEMBL12680483 | 0.75 | AR (0.48) | IMPDH2IMPDH1CCNT1CDK9HASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266892-A1 | AMPK Modulators | MERCURY THERAPEUTICS INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266892-A1 | AMPK Modulators | MERCURY THERAPEUTICS INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150266892-A1 | AMPK Modulators | MERCURY THERAPEUTICS INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-8980895-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980895-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980895-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120302576-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302576-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302576-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. | 2012-11-29 | — | — | US | disclosed |
| US-8273744-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273744-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273744-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2240016-A1 | AMPK MODULATORS | Mercury Therapeutics, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20100009992-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. | 2010-01-14 | — | — | US | disclosed |
| US-20100009992-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. | 2010-01-14 | — | — | US | disclosed |
| US-20100009992-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. | 2010-01-14 | — | — | US | disclosed |
| WO-2009100130-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100130-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266892-A1 | AMPK Modulators | PRKAG1, PRKAG2, PRKAG3 | IMPDH2 876/4885IMPDH1 860/4885CCNT1 3455/4885 |
| US-20120302576-A1 | AMPK MODULATORS | PRKAG1, PRKAG2, PRKAG3 | IMPDH2 876/4885IMPDH1 860/4885CCNT1 3455/4885 |
| US-20100009992-A1 | AMPK MODULATORS | PRKAG1, PRKAG2, PRKAG3 | IMPDH2 876/4885IMPDH1 860/4885CCNT1 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.